Recurrent T Lymphoblastic Lymphoma: Clinical Trials

1 trial for Recurrent T Lymphoblastic Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Active not recruiting 1
Phase 21Active not recruiting 1

Follow Recurrent T Lymphoblastic Lymphoma: new trials by email Literature Review of Recurrent T Lymphoblastic Lymphoma trials Research Report on Recurrent T Lymphoblastic Lymphoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Biospecimen Collection, Computed Tomography, Lumbar Puncture - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Active not recruitingECOG-ACRIN Cancer Research Group402018-08-132026-10-06

Narrower conditions

Burkitt Lymphoma (1)  ·  Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)

Broader conditions

DNA Virus Infections (1)  ·  Epstein-Barr Virus Infections (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Herpesviridae Infections (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Infections (1)  ·  Leukemia (1)  ·  Leukemia, Lymphoid (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoproliferative Disorders (1)

Interventions

Magnetic Resonance Spectroscopy (1)  ·  Specimen Handling (1)  ·  Spinal Puncture (1)  ·  Vincristine (1)  ·  venetoclax (1)

Sponsors

ECOG-ACRIN Cancer Research Group (1)

Countries

Puerto Rico (1)  ·  United States (1)

Top investigators

Neil D Palmisiano (1)

Results publications

PMID 39415930

NIH funding

U10CA180820 (1)